Insider Buying: Femasys (NASDAQ:FEMY) COO Purchases $14,000.00 in Stock

Femasys Inc. (NASDAQ:FEMY) COO John Charles Canning bought 4,375 shares of Femasys stock in a transaction dated Friday, August 7th. The shares were bought at an average cost of $3.20 per share, for a total transaction of $14,000.00. Following the completion of the transaction, the chief operating officer owned 4,375 shares of the company’s stock, valued at approximately $14,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Femasys Stock Down 2.6%

Shares of NASDAQ FEMY opened at $2.29 on Friday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.98 and a current ratio of 3.91. The firm has a market capitalization of $6.92 million, a price-to-earnings ratio of -0.42 and a beta of -2.08. The stock has a 50 day moving average price of $3.67 and a 200 day moving average price of $7.35. Femasys Inc. has a 52-week low of $2.19 and a 52-week high of $22.20.

Institutional Investors Weigh In On Femasys

A number of institutional investors have recently added to or reduced their stakes in FEMY. Kovack Advisors Inc. purchased a new position in Femasys in the fourth quarter valued at about $27,000. Osaic Holdings Inc. purchased a new stake in shares of Femasys during the second quarter valued at about $45,000. HRT Financial LP bought a new stake in shares of Femasys in the 4th quarter valued at about $30,000. Cetera Investment Advisers bought a new stake in shares of Femasys in the 4th quarter valued at about $36,000. Finally, State Street Corp grew its position in shares of Femasys by 43.5% in the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after buying an additional 24,500 shares during the last quarter. Institutional investors own 65.27% of the company’s stock.

Analyst Upgrades and Downgrades

FEMY has been the subject of several research reports. Wall Street Zen upgraded Femasys to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings upgraded Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Femasys currently has a consensus rating of “Hold” and an average price target of $80.00.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.